SKLB-23bb is primarily investigated for its potential therapeutic applications in the field of oncology. It has shown promise as an inhibitor of specific kinases involved in cancer cell proliferation and survival. Research indicates that it may be effective in targeting certain types of tumors, particularly those resistant to conventional treatments. Its mechanism of action involves disrupting signaling pathways that are crucial for cancer progression, making it a candidate for further development in cancer therapy. Additionally, studies are exploring its use in combination with other anticancer agents to enhance efficacy and reduce drug resistance.